Methyl 2-amino-3-thiophenecarboxylate is a useful chemical compound with a variety of research applications. We are pleased to offer high quality Methyl 2-amino-3-thiophenecarboxylate in various sizes (for research, pilot-scale, or production applications) from milligrams to multi-kilogram batches, making it easy for you to choose the right amount to suit your needs.
Methyl 2-amino-3-thiophenecarboxylate [4651-81-4]
or 2-amino-3-carbomethoxythiophene or 2-amino-3-thiophenecarboxylic acid methylester is a white solid with the melting point of 72-73 °C.
Preparation of Methyl 2-amino-3-thiophenecarboxylate:
It can be prepared by modifed Gewald reaction
using methyl cyanoacetate and 1,4-dithiane-2,5-diol in the presence of triethylamine in methanol. 
Application of Methyl 2-amino-3-thiophenecarboxylate:
2-Aminothiophene derivatives are important five-membered building blocks in organic synthesis. Urea derivatives of 2-amino-3-carbomethoxythiophene exhibited promising in vitro cytotoxicity against a human cancer cell lines as an effective binders of ribonucleotidereductase protein.
It was used as a building block in synthesis of various thienopyrimidine derivatives which are interesting structural element in development of pharmaceutical compounds.
Among others, these heterocycles have been used as part of kinase inhibitors to regulate dysfunctional cell signalling in cancer cells,
as calcium receptor antagonists,
as peptidase IV inhibitors
and against hepatitis C virus infections.
Product categorization (Chemical groups):
S. Bugge, S. J. Kaspersen, E. Sundby, B. H. Hoff Tetrahedron 2012
(45), 9226. doi:10.1016/j.tet.2012.08.090
K. Gewald, E. Schinke, H. Böttcher Chem. Ber. 1966
(1), 94. doi:10.1002/cber.19660990116 
J. E. Hempel, A. G. Cadar, C. C. Hong Bioorg. Med. Chem. Lett. 2016
(8), 1947. doi:10.1016/j.bmcl.2016.03.013 
V. Vikram, S. R. Renumutchu, R. Vankayala, S. Thangudu, K. Rao, A. Parimi, U. Parimi J. Chem. Sci. 2020
, 126. doi:10.1007/s12039-020-01834-w 
 V. P. Litvinov Adv. Heterocycl. Chem. 2006
, 83. doi:10.1016/S0065-2725(06)92003-0 
S. J. Baker, P. J. Goldsmith, T. C. Hancox, N. A. Pegg, S. Price, S. J. Shuttleworth, S. Sohal Pyrimidine derivatives as pi3k inhibitors 2006
, F.Hoffmann-La Roche Ag WO2007122410A1
F. Bi, T. Didiuk, A. Guzman-Perez, D. A. Griffith, K. K. C. Liu, D. P. Walker, M. P. Zawistoski Thieno[2,3-d]pyrimidin-4(3h)-one, isoxazolo[5,4-d]pyrimidin-4(5h)-one and isothiazolo[5,4-d]pyrimidin-4(5h)-one derivatives as calcium receptor antagonists 2008
, Pfizer Products Inc. WO2009001214A2
R. L. Stein, A. Case, L. A. Yeh, G. Cuny, E. Duval Substitued 3,4-dihydrothieno [2,3-d] pyrmidines as tissue transglutaminase inhibitors 2005
, The Brigham And Women's Hospital, Inc. WO2006060702A1
J. Deng, L. Peng, G. Zhang, X. Lan, C. Li, F. Chen, Y. Zhou, Z. Lin, L. Chen, R. Dai, H. Xu, L. Yang, X. Zhang and W. Hu Eur. J. Med. Chem. 2010
, 71. 
C. A. Broka, R. T. Hendricks, H. Maag, D. B. Smith, J. Wanner Heterocyclic antiviral compounds 2011
, Roche Palo Alto LLC 20110070190